PDA-
I think we all can agree that there is just no place for whole gland HIFU, except possibly as salvage. That glass is all empty.
With respect to
focal HIFU, I just don't see any advantage over, say, SBRT or HDR-BT (see table in the link below). There is a high re-do rate, incomplete ablation in the ablation zone, probably some toxicity limit on re-dos, and it can only be used on index tumors that are not near the urethra, the rectum or the bladder neck, and the whole theory of index tumors is on shaky ground. What's more, how does anyone use PSA as a tool to monitor success/biochemical failure afterwards? Here's what someone
wrote about
it:
/pcnrv.blogspot.com/2016/12/focal-ablation-unresolved-issues.html(n.b.- the comments at the bottom from a HIFU practitioner and my reply. His HIFU website seems to be gone as well -- I can only find his FLA website)
One legitimate use
may be for the patient who is marginal for AS - perhaps an "index tumor" with a small amount of Gleason pattern 4. By ablating that, and hopefully it would be completely ablated, he may be able to more comfortably stay on AS. But he would still need confirmatory and f/u biopsies, an expert radiologist who knows how to read an mpMRI on ablated tissue, and an expert pathologist who knows how to read a HIFU-ablated biopsy core.
I think the only way HIFU or other innovative focal ablations should be done is within a clinical trial where the patient is fully informed about
all the above risks. These hot-dog urologists who are rushing in to take advantage of a loophole in the law are not doing their patients any favors. I think we need at least 10 years of follow-up to know enough about
it to recommend it. So far, the leaders are the Ahmed/Emberton group in the UK who have published 5-year results that make me uneasy.